-
Mashup Score: 7Novel recommendations for the treatment of patients with heart failure: 2023 Focused Update of the 2021 ESC Heart Failure Guidelines - 8 month(s) ago
The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) generally updates their guidelines every 4 years. However, since the presentation of the latest guidelines in 2021, a remarkable number of studies that could potentially change the guidelines have been published. Therefore, the task force decided to provide a focused update of the 2021 guidelines, which includes a few important novel recommendations that are outlined below (Figure).
Source: www.onlinejcf.comCategories: Cardiologists1, Latest HeadlinesTweet
-
Mashup Score: 7Novel recommendations for the treatment of patients with heart failure: 2023 Focused Update of the 2021 ESC Heart Failure Guidelines - 8 month(s) ago
The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) generally updates their guidelines every 4 years. However, since the presentation of the latest guidelines in 2021, a remarkable number of studies that could potentially change the guidelines have been published. Therefore, the task force decided to provide a focused update of the 2021 guidelines, which includes a few important novel recommendations that are outlined below (Figure).
Source: www.onlinejcf.comCategories: Latest Headlines, Partners & KOLsTweet-
Exceptional new piece from @AdriaanVoors out now in @JCardFail to contextualize new @escardio guidelines “Novel recs for the treatment of pts w HF: 2023 Focused Update” https://t.co/0JfgA7SCm7 https://t.co/m5EFzO1AHl
-
-
Mashup Score: 0
Non-ischemic cardiomyopathy dilated cardiomyopathy is the second most common classification of heart failure. Non-ischemic (DCM) can be attributed to genetic causes in up to 40-50% of cases of familial DCM and in 10-25% of cases of non-familial DCM (Burkett, 2005; Asselbergs, 2021; Huggins, 2022; Hershberger, 2018; Lakdawala, 2012). Given the relatively high prevalence of DCM, genetic testing has become an increasingly important tool for both: a) diagnostic genetic testing to identify genetic subtypes in patients with an existing clinical suspicion for a genetic DCM and b) risk-predictive genetic testing to screen asymptomatic relatives of probands with pathogenic/likely pathogenic variants to identify those at-risk of developing the disease (Landstrom, 2021; Musunuru, 2020).
Source: www.onlinejcf.comCategories: Cardiologists, Latest HeadlinesTweet-
https://t.co/wnwfC7XAbB
-
-
Mashup Score: 20Oral Sodium to Preserve Renal Efficiency in Acute Heart Failure: A Randomized, Placebo-Controlled, Double-Blind Study - 8 month(s) ago
Evidence for modulating the sodium chloride (NaCl) intake of patients hospitalized with acute heart failure (AHF) is inconclusive. Salt restriction may not benefit; hypertonic saline may aid diuresis.
Source: www.onlinejcf.comCategories: Cardiologists, Latest HeadlinesTweet-
RT @JCardFail: Does Oral Sodium benefit patients with AHF? https://t.co/2983Uieioz @robmentz @dranulala @HFSA @DrMarthaGulati @ShelleyZier…
-
-
Mashup Score: 5The CardioNerds #CardsJC: How Twitter Journal Clubs Elevate the Scientific Discourse - 9 month(s) ago
Box representing an inline figure.Box representing an inline figure.Box representing an inline figure.Box representing an inline figure.Box representing an inline figure.
Source: www.onlinejcf.comCategories: Cardiologists, Latest HeadlinesTweet-
RT @AmitGoyalMD: What a terrific discussion on EXPLORER & VALOR HCM. The value of Twitter Journal Clubs: https://t.co/sstaYbwk64 @JCardFa…
-
-
Mashup Score: 15Sex Differences in Heart Failure - 9 month(s) ago
Despite increased awareness and major advancements in prevention and treatment, cardiovascular disease (CVD) persists as the leading cause of death worldwide, for men and women.1 Important sex-based differences exist, and heart failure (HF) represents one of the most serious and prevalent manifestations of disease wherein these differences are apparent and relevant. Inherent biological distinctions in the structure and function of the cardiovascular system between men and women underlie sex-based differences in risk factors, pathophysiology, clinical presentation, diagnosis, and response to treatment.
Source: www.onlinejcf.comCategories: Expert Picks, Latest HeadlinesTweet-
The amazing @dranulala presenting at #cmhcwomensmc discussing sex differences in #heartfailure @JCardFail 📎 https://t.co/zs4NMBWrrZ https://t.co/vHcvnc9778
-
-
Mashup Score: 3Language Matters: Understanding Barriers to Medication Adherence to Better Tailor Heart Failure Care - 9 month(s) ago
History of Present Illness: “A 47 year-old man is admitted with acute heart failure in the setting of medication non-adherence (non-compliance).”
Source: www.onlinejcf.comCategories: Cardiologists, Latest HeadlinesTweet-
@DrNasrien Could not agree more! @dranulala helped teach me this concept - let’s talk about “barriers to adherence” - then we’re better positioned to work on solutions @ShelleyZieroth @DrMarthaGulati @vbluml @hvanspall @AndrewJSauer https://t.co/2KY6ZrmUt4
-
-
Mashup Score: 7Aficamten for Drug-Refractory Severe Obstructive Hypertrophic Cardiomyopathy in Patients Receiving Disopyramide: REDWOOD-HCM Cohort 3 - 10 month(s) ago
How this work applies to patients
Source: www.onlinejcf.comCategories: Cardiologists, Latest HeadlinesTweet-
Aficamten on top of disopyramide and AVN blocker - REDWOOD-HCM Cohort 3 manuscript is now out in @JCardFail Aficamten was safe (3 neg intropes), no interaction with disopyramide, and effective in reducing LVOTO (figures) Link: https://t.co/B2qR4UZgxN #CardioTwitter #HCM https://t.co/wI3G73VZUz
-
-
Mashup Score: 14
GLP-1 receptor agonists (GLP-1 RA) are usually described as having beneficial effects on atherosclerotic cardiovascular disease (ASCVD) and neutral effects on heart failure (HF) events. However, recent data suggest that the effect of GLP-1 RA may differ according to baseline HF status, with decreased risk of HF events in those without established HF and increased risk of HF events among those with HF with reduced ejection fraction (HFrEF).1–4 Treatment with GLP1-RA liraglutide did not improve clinical stability in the FIGHT (Functional Impact of GLP-1 for Heart Failure Treatment) trial and did not improve left ventricle ejection fraction (LVEF) in the LIVE (Effect of Liraglutide on Left Ventricular Function in Stable Chronic Heart Failure Patients with and without Diabetes) trial.
Source: www.onlinejcf.comCategories: Expert Picks, Latest HeadlinesTweet-
RT @JCardFail: The latest from JCF Ignite! 🧵 https://t.co/vpZLFHlh16 @robmentz @dranulala @HFSA @DrMarthaGulati @ShelleyZieroth @vbluml @Q…
-
-
Mashup Score: 1Current Issue Table of Contents: Journal of Cardiac Failure - 1 year(s) ago
Editor’s Page: We’ve been thinking…Constructive Criticism in Medicine: Heart Function Clinicians Leading Positive ChangeRobert J. Mentz,Anuradha LalaPublished in issue: March 2023p233-235Full-Text HTMLPDF Original Research PapersSudden Cardiac Death in Heart Failure: A 20-Year Perspective From a Mediterranean CohortPAU Codina,ELISABET ZAMORA,WAYNE C LEVY,…ALBERTO AIMO,JOSEP…
Source: www.onlinejcf.comCategories: Cardiology News and Journals, Latest HeadlinesTweet-
March's Issue of @JCardFail exclusively online - is now available! ▶️ Sudden Cardiac Death in Heart Failure ▶️ Practical Considerations with Use of Vericiguat ▶️ Frequency and Predictors of Falls Among Adults with HF Read more >> https://t.co/AadOCw9byC https://t.co/8N39zNDqrH
-
RT @Office_j: 【備忘】 J Card Fail誌に、 ESC心不全ガイドライン「2023年部分改訂版」の要約と解説。４項目に分けて概説。 https://t.co/Xpv0dcGMIP